Dan Markingson was a 26-year-old mentally ill young man who violently killed himself in 2004 while enrolled in a drug-sponsored study of atypical antipsychotics among persons experiencing psychosis for the first time. Highly vulnerable individuals like Markingson should not be taken advantage of in the name of scientific research, and inability to protect such vulnerable subjects compromises the integrity of research.
Study of students without an ADHD diagnosis finds that stimulants (Adderall) have little impact on cognitive performance.
Three out of four users of the sedative, zolpidem (brand name Ambien), do not follow FDA recommendations to reduce risk.
I believe this is what happened: The people responsible for this travesty looked at the truth (that psychiatrists hardly ever tell the truth about their drugs) and realised they didn't like what would flow from that fact getting loose. So they removed it and substituted a falsehood (only ever) whose consequences they could live with.
Researcher and former service-user Diana Rose utilizes a participatory research process to examine experiences on inpatient wards.
Study details Medicaid-insured birth cohort’s exposure to psychiatric medications and mental health services.
A new study in JAMA Psychiatry found that transcranial magnetic stimulation was no better than placebo for treatment-resistant depression.
Researchers take action after study exposes enduring sexual dysfunction as a potential side effect of serotonin reuptake inhibiting antidepressants, 5α-reductase inhibitors, and isotretinoin.
The BMJ’s clinical editor takes issue with uncritical media coverage of antidepressant network meta-analysis, outlining reporting missteps.
A new study finds that stimulant prescribing rates to children continue to rise despite the well-established evidence documenting overdiagnosis of ADHD and overprescription of stimulants.
The most important data in an RCT is not whether the drug provides a statistically significant benefit over placebo. The most important data is the “number needed to treat” calculation (NNT). For the person considering taking an antidepressant or an antipsychotic, the NNT data provides the “math” needed to weigh the potential benefit of taking the drug against the potential harm of doing so.
Dr. Johnathan Shedler recently published a paper critiquing how the term “evidence-based” is being used in the field of psychotherapy.
New guidelines recommend deprescribing benzodiazepine receptor agonists for adults.
Results from a Cochrane meta-analysis find that the common practice of prescribing antidepressants to treat insomnia is not supported by current evidence.
Paper outlines recommendations for more thorough informed consent process in psychotherapy, which authors proclaim is an “ethical imperative."
A new review, published in The Lancet Psychiatry, examines the perspectives of clinicians and service-users on psychiatric diagnosis.
How did I become someone who could barely function? I was a high-performing sales executive ranked in the top 2% of an international business communications company. But now, after using powerful psych meds for depression and anxiety for more than a decade, I couldn’t do basic things like go to the grocery store, plan a meal, make dinner, or get together with friends.
A discussion of the role of epistemic injustice in the experiences of patients diagnosed with psychiatric disorders.
Few DTC drug advertisements fully adhere to FDA guidelines, the overall quality of information provided in DTC advertisements is low, and some advertisements market off-label indications.
My life flashed before my eyes as my entire medical history over the last decade was rewritten from having a genetic brain disease to being a victim of a medical scam. It was bittersweet, for I realized that I was not sick and dying, but I had been robbed of so many years of my life due to the psychiatrist’s lies. Now I am suing my former psychiatrist for damages.
Psychostimulant prescriptions have increased by 344% (from 2003 to 2015) for women of reproductive age (15-44 years old).
Long-term benzodiazepine use shown to effect cognitive function during current use and for years after drug discontinuation.
Corruption of pharmaceutical industry sponsored clinical trials identified as a “major obstacle” facing evidence-based medicine.
An investigation exposes violations to research ethics, finding that researchers failed to disclose risks and even misled government agencies.
Researchers Identify risk factors for long-term benzodiazepine use to prevent harmful effects.